Lacidipina Doc Generici

Lacidipine, the active ingredient in Lacidipine Doc Generici, is a calcium channel blocker presented as a tablet for oral use. By inhibiting L‑type calcium channels, it promotes vasodilation and reduces peripheral vascular resistance, thereby lowering elevated blood pressure in adults with hypertension.

GNH USA supplies Lacidipine Doc Generici as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Lacidipine is indicated for conditions related to the cardiovascular system where reduction of blood pressure is required.

- Essential hypertension: reduces systolic and diastolic blood pressure. - Isolated systolic hypertension: provides targeted reduction of systolic pressure. - High‑risk hypertensive patients: contributes to overall cardiovascular risk management.

Lacidipine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache - Flushing - Peripheral edema - Dizziness - Tachycardia - Nausea

Serious or Rare Side Effects: - Severe hypotension - Myocardial infarction - Hepatic dysfunction - Allergic reactions (rash, urticaria) - Angioedema - Cardiac arrhythmias

When prescribing or dispensing lacidipine, several safety considerations should be observed.

- Blood pressure monitoring: check regularly to avoid excessive hypotension. - Liver function assessment: evaluate hepatic enzymes before initiating therapy. - Elderly patients: start with lower dose and monitor for dizziness. - Concomitant antihypertensives: adjust doses to prevent additive effects. - Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. - Store at room temperature: keep in original packaging, protect from moisture and light.

Lacidipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lacidipine plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Other potent vasodilators (e.g., nitroglycerin): risk of severe hypotension.

Moderate Interactions (Monitor Closely): - Grapefruit juice: can modestly raise lacidipine concentrations. - Diuretics: may enhance antihypertensive effect, requiring dose adjustment. - Beta‑blockers: additive blood pressure lowering. - Digoxin: possible increase in serum digoxin levels.